- Home
- RMI vs MGNX Comparison
RMI vs MGNX Comparison
Compare RMI & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMI
- MGNX
- Stock Information
- Founded
- RMI 2018
- MGNX 2000
- Country
- RMI United States
- MGNX United States
- Employees
- RMI N/A
- MGNX N/A
- Industry
- RMI Finance/Investors Services
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- RMI Finance
- MGNX Health Care
- Exchange
- RMI Nasdaq
- MGNX Nasdaq
- Market Cap
- RMI 91.2M
- MGNX 99.7M
- IPO Year
- RMI N/A
- MGNX 2013
- Fundamental
- Price
- RMI $13.93
- MGNX $1.58
- Analyst Decision
- RMI
- MGNX Hold
- Analyst Count
- RMI 0
- MGNX 5
- Target Price
- RMI N/A
- MGNX $3.25
- AVG Volume (30 Days)
- RMI 17.4K
- MGNX 628.1K
- Earning Date
- RMI 01-01-0001
- MGNX 08-14-2025
- Dividend Yield
- RMI 7.28%
- MGNX N/A
- EPS Growth
- RMI N/A
- MGNX N/A
- EPS
- RMI N/A
- MGNX N/A
- Revenue
- RMI N/A
- MGNX $165,495,000.00
- Revenue This Year
- RMI N/A
- MGNX N/A
- Revenue Next Year
- RMI N/A
- MGNX N/A
- P/E Ratio
- RMI N/A
- MGNX N/A
- Revenue Growth
- RMI N/A
- MGNX 303.47
- 52 Week Low
- RMI $13.05
- MGNX $0.99
- 52 Week High
- RMI $17.37
- MGNX $5.10
- Technical
- Relative Strength Index (RSI)
- RMI 40.36
- MGNX 50.75
- Support Level
- RMI $13.71
- MGNX $1.43
- Resistance Level
- RMI $14.22
- MGNX $1.67
- Average True Range (ATR)
- RMI 0.14
- MGNX 0.12
- MACD
- RMI 0.01
- MGNX -0.01
- Stochastic Oscillator
- RMI 43.14
- MGNX 52.63
About RMI RiverNorth Opportunistic Municipal Income Fund Inc.
RiverNorth Opportunistic Municipal Income Fund, Inc. is a diversified, closed-end management investment company. Its investment objective is to seek current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.